Drug Profile
Research programme: anti-infectives - Xellia Pharmaceuticals
Latest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator Xellia Pharmaceuticals
- Developer SINTEF Materials and Chemistry; Statens Serum Institut; Xellia Pharmaceuticals
- Class Antibacterials; Polymixins
- Mechanism of Action Cell membrane modulators; Cell wall inhibitors; Lipopolysaccharide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cystic fibrosis-associated respiratory tract infections; Gram-negative infections; Gram-positive infections
Most Recent Events
- 27 Mar 2023 Early research is ongoing in Norway for Cystic fibrosis-associated respiratory tract infections, Gram-negative infections and Gram-positive infections (Xellia Pharmaceuticals website, March 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Cystic-fibrosis-associated-respiratory-tract-infections in Norway (Parenteral, Inhalant)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Gram-positive-infections in Norway (Parenteral)